The History of Stem Cell Hair Research: From Mouse Models to Human Trials

Stem cell hair research has moved from studies of how follicles work to early human trials, but it has not yet produced a proven way to grow and transplant new follicles. The story spans research on follicle stem cells and dermal papilla cells, followed by small, varied clinical studies in several countries. These studies offer scientific leads—not a guarantee that a treatment will restore hair.

From the follicle bulge to a focus on stem cells

The hair follicle’s bulge region became central to research because it contains hair follicle stem cells (HFSCs), which can remain viable even as pattern hair loss progresses. Researchers have therefore explored whether these cells, or signals that influence them, could help support hair growth. This is different from saying that stem cells can reliably create a new, fully functioning follicle in a person.

A key insight is that pattern hair loss involves more than simply losing every stem cell in an affected area. Hair progenitor cells may be depleted while HFSCs remain, and changes in signaling can interfere with the follicle’s normal growth cycle (a review of stem-cell-based approaches to hair loss). This helped shape a range of research strategies, including cell transplantation, micrografts and products intended to deliver cell-derived signals.

Early laboratory and animal research, including mouse-model work, helped scientists investigate how follicles develop and respond to biological signals. But results in models do not establish that a treatment will work in people. A lab-grown follicle would also need to cycle, connect with surrounding tissue, develop a blood supply and produce pigment—requirements that make functional follicle regeneration a complex challenge (a review of follicle regeneration).

Why dermal papilla cells matter

The dermal papilla (DP) is a specialized group of cells at the base of a hair follicle. DP cells help regulate hair growth and the follicle’s cycle, making them an important target in regenerative research. In pattern hair loss, androgen-related changes can disrupt DP signaling and pathways involved in follicle growth, including Wnt-beta-catenin signaling (Tosti and colleagues’ review).

This research has encouraged scientists to ask whether cells from the dermal papilla, or signals from other cell types, could help weakened follicles. It does not mean that a DP-cell procedure can currently generate durable new follicles. Research approaches have included cells from hair follicles, adipose tissue, bone marrow and umbilical cord blood, as well as conditioned media and extracellular vesicles. The methods and proposed mechanisms differ, so the label “stem cell treatment” alone does not tell a patient what is actually being offered.

Human studies across countries, 2015–2021

A 2023 systematic review examined 15 human studies involving 653 participants, conducted from 2015 through 2021. The studies came from Italy, Egypt, Saudi Arabia, Japan, Spain and South Korea, and five were randomized controlled trials. They investigated several approaches, including HFSC-containing micrografts, dermal sheath cup cells, adipose-derived cells and bone-marrow-derived cell preparations (the systematic review in Cells).

The review reported increased hair density across the included studies, but its authors also noted important limitations: small participant groups, different treatment protocols and short follow-up periods. These differences make it difficult to compare results or know how long any improvement may last. A positive finding in a small study is a reason for further research, not proof that a treatment will work for every patient.

For patients, the distinction between research and routine care matters. Many Hair Transplant Clinics may discuss regenerative options, but patients should ask what cells or products are used, whether the treatment is part of a registered clinical study, and what published human evidence applies to that specific method. A Hair Transplant Clinic should also explain that established FUE and FUT surgery redistribute a patient’s existing follicles; they do not create lab-grown follicles (ISHRS patient guide).

What the research does—and does not—offer today

Stem-cell-related research includes cell transplantation or micrografts, conditioned media and exosomes. These are not interchangeable treatments. The FDA states that no regenerative medicine product is approved for hair loss, and a procedure that grows new follicles in a laboratory and transplants them is not an established clinical option (FDA information for patients).

That status makes clear questions especially useful during a consultation: What exactly is being injected or applied? What evidence supports that particular product and protocol? What outcomes were measured, and for how long? Patients should also ask about risks, costs and alternatives, and should not assume that a treatment is proven because it is described as “regenerative” or “stem cell-based.”

Frequently Asked Questions

Did stem cell research lead to hair cloning?

Not yet. Creating a functional follicle in a laboratory remains a research challenge, and hair cloning or follicle regeneration is not clinically available (the follicle regeneration review). Current hair transplantation moves existing follicles rather than adding newly grown ones.

Do human studies show that stem cell treatments work?

Some human studies reported increased hair density, but the studies reviewed were small and used varied methods, with limited follow-up. The evidence is promising enough to study further, but it does not establish a reliable outcome for an individual patient (the 2023 systematic review).

How can I evaluate a treatment marketed as regenerative?

Ask for the exact treatment name, ingredients or cell source, published evidence for that protocol, and whether it is being studied in a clinical trial. FDA approval should not be assumed: no regenerative medicine product is FDA-approved for hair loss (FDA patient information).

Stem cell hair research has progressed from follicle biology and experimental models to early studies in people, but important questions remain. For now, patients benefit from clear explanations of what is established, what is experimental and what a proposed treatment can realistically be expected to do.